Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory, Autoimmune, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCL10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCL10 Recombinant Protein High purity (>95%), Endotoxin controlled (<1 EU/μg). Sequence Verified. HEK293 expressed for native conformation. |
View CXCL10 Products |
| Gene Delivery | CXCR3 Lentiviral Particles Full-length human CXCR3 (GPCR) ORF for stable cell line generation. Optimized for chemotaxis assays. |
View CXCR3 Products |
| Benchmark Ab | Anti-CXCL10 Recombinant Antibody Biosimilar sequence based on Eldelumab. Recombinant rabbit/human IgG positive control. |
View CXCL10 Products |
| Validator | CXCL10 siRNA Set Target-specific knockdown pool for specificity and functional verification. |
View CXCL10 Products |
| Related Target A | CXCR3 The primary G-protein coupled receptor for CXCL10, mediating chemotaxis and downstream signaling. |
View CXCR3 Products |
| Related Target B | CXCL9 Synergistic CXCR3 ligand; critical for selectivity screening and off-target profile evaluation. |
View CXCL9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species translation (Human vs. Rodent homology) | Human, Mouse, and Cynomolgus CXCL10 ortholog proteins available with >95% purity |
| Subfamily counter-screening (CXCL9/11 cross-reactivity) | Homolog panel proteins (CXCL9, CXCL11) strictly verified by Mass Spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Eldelumab biosimilar) included |
| False Positives | Validated siRNA included for target knockdown and specificity checks |
Live CXCL10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the CXCL10/CXCR3 axis is undergoing a significant renaissance. Initially pursued for autoimmune diseases like Ulcerative Colitis and Rheumatoid Arthritis, the focus has expanded dramatically. Today, the race for CXCL10 therapeutics is intensifying, with major players shifting focus from traditional systemic mAbs to localized delivery, bispecific/multispecific antibodies, and combination regimens in oncology. As first-generation therapies reach the clinic, the next wave of R&D is targeting the modulation of the "cold" to "hot" tumor microenvironment by leveraging CXCL10-mediated T-cell recruitment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Bristol Myers Squibb, Janssen | Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis | High-affinity neutralization assays (Need HEK293-expressed CXCL10) |
| Bispecific Antibody | Innovent, Roche | Solid Tumors, Immune-mediated Inflammatory Diseases | Dual-targeting binding kinetics (Need high-purity CXCL10 and partner antigens) |
| Small Molecule (CXCR3 Antagonist) | Sanofi, Actelion | NASH, Fibrotic Diseases, Psoriasis | Cell-based functional assays (Need CXCR3 Lentivirus for stable cell line construction) |